Abbott India's Q4 profit increased 24% to 2.87 billion rupees, driven by sales growth despite govt pricing caps.
Abbott India, a drug manufacturer, saw a 24% increase in Q4 profit to 2.87 billion rupees ($34.3m) driven by sales growth, despite government pricing caps on some medicines. The company's revenue from operations increased by 7% to 14.39 billion rupees in Q4. Abbott India, a subsidiary of U.S. healthcare firm Abbott Laboratories, declared a dividend of 410 rupees per share for fiscal year 2024.
May 09, 2024
3 Articles